Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN 70 30 versus HUMULIN R KWIKPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN 70 30 versus HUMULIN R KWIKPEN.
HUMULIN 70/30 vs HUMULIN R KWIKPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin replacement therapy. Human insulin is a recombinant DNA-derived polypeptide hormone that regulates glucose metabolism. Insulin binds to the insulin receptor, activating tyrosine kinase activity, which leads to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, adipose tissue), inhibition of hepatic gluconeogenesis, and promotion of glycogen synthesis and lipogenesis.
Insulin lispro lowers blood glucose by binding to insulin receptors, increasing glucose uptake in skeletal muscle and adipose tissue, and inhibiting hepatic glucose production.
Subcutaneous injection, 0.5-1.0 units/kg/day divided into two doses (before breakfast and before dinner), adjusted based on blood glucose monitoring.
Subcutaneous injection, individualize based on metabolic needs and blood glucose monitoring. Typical starting total daily insulin dose in type 1 diabetes: 0.5-1 unit/kg/day, with 50-60% as basal and 40-50% as prandial. In type 2 diabetes, initial total daily dose: 0.2-0.4 units/kg/day, with adjustments. Administer 30 minutes before meals.
None Documented
None Documented
0.5-1 hour (free insulin); 8-12 hours (prolonged due to NPH component, reflecting duration of action).
5-10 minutes (intravenous); subcutaneous: 1.5-2 hours (depot absorption-limited).
Renal: 100% (metabolized to inactive fragments; negligible excretion of intact insulin).
Renal: 60-80% (metabolized to inactive peptides); hepatic metabolism via insulin-degrading enzyme; remainder reabsorbed in proximal tubule.
Category C
Category C
Human Insulin
Human Insulin